NASDAQ: MLYSMineralys Therapeutics Inc Stock
$13.94+0.38 (+2.8%)
Updated Apr 29, 2025
MLYS Price
$13.94
Fair Value Price
$2.35
Market Cap
$694.71M
52 Week Low
$8.24
52 Week High
$18.38
P/E
-3.81x
P/B
3.63x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$177.81M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.08
Operating Cash Flow
-$166M
Beta
1.01
Next Earnings
May 7, 2025
Ex-Dividend
N/A
Next Dividend
N/A
MLYS Overview
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MLYS's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
MLYS
Ranked#227 of 462
Ranked#227 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.96 | A | |
| $8.12 | A | |
| $24.28 | A |
Be the first to know about important MLYS news, forecast changes, insider trades & much more!
MLYS News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MLYS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MLYS ($13.94) is overvalued by 493.07% relative to our estimate of its Fair Value price of $2.35 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
MLYS ($13.94) is not significantly undervalued (493.07%) relative to our estimate of its Fair Value price of $2.35 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
MLYS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more MLYS due diligence checks available for Premium users.
Valuation
MLYS fair value
Fair Value of MLYS stock based on Discounted Cash Flow (DCF)
Price
$13.94
Fair Value
$2.35
Overvalued by
493.07%
MLYS ($13.94) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MLYS ($13.94) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MLYS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MLYS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.81x
Industry
-158.75x
Market
29.19x
MLYS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.63x
Industry
4.37x
MLYS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MLYS's financial health
Profit margin
Revenue
$0.0
Net Income
-$48.9M
Profit Margin
0%
MLYS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$205.9M
Liabilities
$14.6M
Debt to equity
0.08
MLYS's short-term assets ($205.35M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MLYS's short-term assets ($205.35M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MLYS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$66.8M
Investing
$83.6M
Financing
$90.0k
MLYS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MLYS vs Biotech Stocks
Mineralys Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.